2,4-Diaminopyrimidine DHFR Inhibitors for Selective Pathogen Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pathogenic infections caused by Bacillus, Cryptosporidium, Toxoplasma, and Candida species face challenges such as high costs, resistance, and limited efficacy, particularly in immune-compromised patients, and existing DHFR inhibitors lack selectivity and potency against these pathogens.
Innovation Solution
Development of pyrimidine derivatives with a 2,4-diaminopyrimidine ring system and a propargyl linker to inhibit dihydrofolate reductase (DHFR) enzymes in bacterial, fungal, and protozoal organisms, offering potent and selective inhibition with low molecular weight and minimal toxicity to mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing DHFR inhibitors are used to treat pathogenic infections, then some therapeutic effect is achieved, but selectivity and potency against specific pathogens (Bacillus, Cryptosporidium, Toxoplasma, Candida) are insufficient
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (2,4-diaminopyrimidine core with particular substituent patterns) that create selective binding affinity for pathogenic DHFR enzymes while avoiding human DHFR. The structural modifications at specific positions of the molecule enable differential interaction with conserved and variable residues in the active site, achieving pathogen-specific inhibition without affecting mammalian cells.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular weight, hydrophobicity, and structural parameters of the inhibitor compounds. The optimized molecules have molecular weights in a specific range (300-500 Da) and incorporate hydrophobic substituents that enhance binding to pathogenic DHFR while maintaining cell permeability. These parameter optimizations enable potent inhibition of pathogenic organisms with minimal toxicity to mammalian cells.
2Reliability
If current therapeutics for B. anthracis infections are used, then treatment is provided, but limitations include expense, resistance and contraindications in children
Solution Approach 1:
The patent develops small-molecule DHFR inhibitors with molecular weights suitable for oral administration and standard pharmaceutical formulation. These compounds are designed to be cost-effective alternatives to expensive existing therapies, with simple chemical structures that enable scalable synthesis. The inhibitors target an essential enzyme in folate metabolism, providing reliable efficacy against B. anthracis without the complexity and cost of current treatment regimens.
3Reliability
If DHFR inhibitors are designed to be potent against pathogenic organisms, then therapeutic effectiveness increases, but selectivity decreases leading to broader toxicity
Solution Approach 1:
The patent achieves selective potency by incorporating specific substituent patterns on the 2,4-diaminopyrimidine core that interact with pathogen-specific residues in the DHFR active site. The molecular design targets conserved catalytic residues while exploiting variable regions in pathogenic DHFR enzymes, creating high-affinity binding that is selective for pathogens over human cells. This local structural optimization enables potent anti-pathogen activity without broad-spectrum toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The pyrimidine derivatives demonstrate strong antifungal, antibacterial, and antiprotozoal activity, providing a broad-spectrum treatment option with reduced side effects and improved selectivity, potentially addressing the limitations of existing therapies.
Implementation Method 1
DHFR utilizes the cofactor NADPH to catalyze the reduction of dihydrofolate to tetrahydrofolate, thereby performing a key reaction in the sole de novo synthesis of deoxythymidine monophosphate (dTMP).
Data Source
AI summary
The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.